AbbVie Inc (ABBV)vsAlpha Teknova Inc (TKNO)
ABBV
AbbVie Inc
$230.01
+6.25%
HEALTHCARE · Cap: $391.50B
TKNO
Alpha Teknova Inc
$5.13
-0.97%
HEALTHCARE · Cap: $235.90M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 150177% more annual revenue ($62.82B vs $41.80M). ABBV leads profitability with a 5.8% profit margin vs -41.1%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
TKNO
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$230.01
$83.79 premium
Intrinsic value data unavailable for TKNO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -26.4% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : TKNO
The strongest argument for TKNO centers on Debt/Equity. Revenue growth of 13.1% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : TKNO
The primary concerns for TKNO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while TKNO is a turnaround play — different risk/reward profiles.
TKNO carries more volatility with a beta of 0.63 — expect wider price swings.
TKNO is growing revenue faster at 13.1% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 28/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Alpha Teknova Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alpha Teknova Inc (TKNO) is a leading entity in the synthetic biology sector, specializing in the production of vital biological reagents and supplements that cater to life sciences research and biomanufacturing. The company's offerings play a pivotal role in high-demand areas such as vaccine development, cell and gene therapy, and diagnostic testing, underscored by a commitment to quality and exceptional customer service. With a robust biotechnology foundation and a strong focus on innovation, Alpha Teknova is well-equipped to capitalize on growth opportunities in the rapidly evolving life sciences market, positioning itself as a valuable investment for institutional stakeholders.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?